retatrutide side effects clinical trials 2025 Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial 1 Month Retatrutide Results: Clinical

Both short- and long-acting GLP-1s have been shown to improve glycemic control and drive weight loss in a range of randomized controlled trials (RCTs)

Starting at $599 per month, some people were able to get prescribed to Wegovy and a Hims & Hers membership

It is also popular with busy professionals who prefer privacy and convenience, plus active adults who want a simple recovery-focused routine

NICE recommends GLP-1 receptor agonists for type 2 diabetes when triple oral therapy fails or in specific BMI and comorbidity contexts, with six-month review required

These medications mimic natural hormones that regulate hunger and blood sugar, helping many patients lose 15% or more of their body weight